Our people are our
most valuable asset
Our Management, Board of Directors, and Scientific Advisory Board are comprised of world-class drug development experts with proven expertise in cancer and fibrosis. Our team shares a collective vision to improve the treatment paradigm in these disease areas by developing better therapies.
Meet Our Team
Cathy A. Swindlehurst, Ph.D.
Dr. Swindlehurst is a founder and CEO of NovoMedix. She has over 30 years of experience in biotech and has a broad background in assay and biomarker development; drug discovery and development; as well as in project management, business development, and fund raising. Dr. Swindlehurst has held V.P. positions at several companies, including PanCel , MagneSensors, and NovaDx. She has led key collaborations with academic researchers and corporate partners. Dr. Swindlehurst is an inventor on NovoMedix’s key issued patents. Dr. Swindlehurst received a certificate in Business Management from UC San Diego; Ph.D. in Analytical Chemistry and Postdoctoral fellowship in Immunology from University of Illinois, Champaign Urbana. Dr. Swindlehurst is the author of numerous publications and an inventor on over 40 issued patents.
Kyle W.H. Chan, Ph.D.
Dr. Chan is a cofounder and CSO of NovoMedix, LLC and has over 30 years of experience in drug discovery and development. He was the cofounder and Chief Technology Officer of BioTheryX, Inc., a clinical-stage targeted protein degrader company. Dr. Chan was formerly the head of Discovery Research at Celgene where he built and led technology programs in genomics, proteomics, and informatics as well as successfully managed therapeutic programs in virology, estrogen physiology, and the development of small molecule modulators of epigenetic programming and adult stem cells for regenerative medicine. He has served on scientific and business advisory boards for a number of biotech companies. Dr. Chan received his Ph.D. in electroanalytical chemistry from the University of Illinois, Urbana-Champaign; a post-doctoral fellowship in biophysics from UC San Diego; authored numerous publications and holds over 30 U.S. patents.
Laura G. Corral, M.S.
Laura Corral has over 30 years of experience in drug discovery and cell biology research in the pharmaceutical industry. She started her industrial career as a Research Scientist at Celgene Corp. working in close collaboration with scientists at Rockefeller University. She was part of the small group of scientists led by Dr. David Stirling that performed in vitro and in vivo screening, characterization and optimization of thalidomide analogs, a project that led to the identification of a novel class of compounds known as IMiDs®. Two of these drugs, lenalidomide and pomalidomide, have received regulatory approval in several countries for oncological indications. In addition, Ms. Corral characterization of novel drug candidates contributed to the identification of a PDE4 inhibitor, apremilast, recently approved for the treatment of psoriatic arthritis. Ms. Corral developed new primary cell based assays in an effort to study to mechanism of action of IMiDs® . This effort uncovered different activities of thalidomide analogs, including effect on stem cells expansion and differentiation and antiproliferative effects in leukemic cells from patients. Ms. Corral received her M.S. degree in Cell Biology from New York University and a B.S. degree from the Federal University of Rio de Janeiro.
Meet Our Team
Board of Directors & Advisors
David I. Stirling, Ph.D.
Lawrence is a Director of NovoMedix. He was a cofounder and the President of BioTheryX, Inc., a clinical stage targeted protein degrader company. Lawrence was a founding Managing Director of Amphion Innovations Plc., a company that creates, operates and finances life science and technology companies in partnership with corporations, governments, universities and entrepreneurs. Mr. Zaslow was also a consultant to Amphion until July, 2009. Prior to joining Amphion, Mr. Zaslow was primarily engaged for over 25 years in raising capital for a number of start-up biotechnology companies, including the initial public offering for Celgene in 1987. Mr. Zaslow received his BA in economics from Brandeis University and his MBA in finance from the Columbia Graduate Business School.
Fadi N. Salloum, Ph.D.
Dr. Salloum is the Natalie N. and John R. Congdon Sr. Endowed Chair at Virginia Commonwealth University (VCU) Health Pauley Heart Center. He received his PhD at VCU and completed his postdoctoral fellowship training in Molecular Cardiology in the Department of Internal Medicine at VCU. Dr. Salloum’s research focuses on understanding the molecular mechanisms and signaling pathways of cardiopulmonary and metabolic diseases in order to develop novel therapies to treat them. His laboratory is also focused on studying the role of novel or ‘repurposed’ drugs in cardioprotection against ischemia-related injury and adverse cardiac remodeling/failure through suppression of the NLRP3 inflammasome, as well as investigating methods to mitigate cardiotoxicity induced by various standard-of-care cancer chemotherapeutic drugs. Dr. Salloum served on the American Heart Association’s new Strategically Focused Research Network (SFRN) peer-review panel on heart failure and continuously serves as ad hoc reviewer on NIH study sections. He currently Co-Chairs the American Heart Association’s Cardiac Bio BSc 3 Peer-Review Committee. With over 100 peer-reviewed publications, Dr. Salloum has numerous active NIH-funded grants and has been previously funded by several AHA and Industry grants.
Douglas Flanagan, Ph.D.
Dr. Flanagan is a Emeritus Professor of Pharmaceutics and Chemical & Biochemical Engineering and former Division Head of the Pharmaceutics Division in the College of Pharmacy at the University of Iowa. With nearly 90 publications and over 100 presentations at scientific meetings, Dr. Flanagan has 40 years experience teaching about and developing drug formulations and biopharmaceutics. He has had numerous collaborative grants with government agencies and partnerships with pharmaceutical companies such as Bristol-Myers Squibb, Abbott Laboratories, Axonyx, and over 25 other firms, working on controlled drug delivery systems and formulations. Many of these collaborative efforts and partnerships have come through his over 30 year relationship with the University of Iowa Pharmaceuticals (UIP). UIP is a FDA-registered clinical manufacturer which has provided to formulation development and production services to the pharmaceutical industry and government agencies for over 40 years.
Shile Huang, PhD
Dr. Huang’s major research is in studying mTOR signaling in tumorigenesis, cell signlaing, and metastasis. mTOR functions as two complexes, mTORC1 and mTORC2, and regulates cell proliferation, growth (cell size), and survival. Dr Huang demonstrated that mTOR also regulates cell motility. Disruption of mTORC1 or mTORC2 by silencing the expression of raptor or rictor down-regulates cell motility, implicating critical roles of mTORC1 and mTORC2 in this cellular process. He is currently focusing on identifying the molecular mechanisms by which mTORC1 and mTORC2 regulate cell motility. In addition, the laboratory is investigating anticancer mechanisms of small molecules such as curcumin, cryptotanshinone, artemisinin, and ciclopirox olamine. Curcumin, cryptotanshinone, and artemisinin are natural products isolated from the plants Curcuma longa, Salvia miltiorrhiza, and Artemisia annua, respectively, whereas ciclopirox olamine is an off-patent synthetic fungicide. Notably, curcumin, artesunate (a water-soluble artemisinin derivative), and ciclopirox olamine are undergoing initial clinical trials as novel anticancer agents. However, the anticancer mechanisms of these compounds remain to be elucidated. Dr. Huang’s recent studies indicate that they may execute their anticancer activities by inhibiting cell proliferation, inducing cell death, suppressing cell motility, or inhibiting angiogenesis/lymphangiogenesis. Dr. Huang is currently elucidating the molecular mechanisms underlying these effects.
Robert E. Rhoads, Ph.D.
Dr. Rhoads is curently Professor Emeritus at LSU and formerly Professor and Head of the Department of Biochemistry and Molecular Biology at the LSU Health Sciences Center in Shreveport. Dr. Rhoads has been funded by the NIH for over 36 years to study the mechanism and regulation of eukaryotic protein synthesis, especially as it relates to messenger RNA structure and function, translational control of gene expression, biochemistry and biophysics of initiation factors, regulation of cell growth, and viral pathogenesis involving translation. Current interests include recognition of mRNA by the translational machinery, determinants of mRNA stability, hormonal regulation of protein synthesis in mammary epithelial cells, epithelial-mesenchymal transition, and translational control of meiotic crossing-over and embryogenesis. His laboratory was the first to clone and sequence the cDNAs for the protein synthesis initiation factors eIF4E (cap-binding protein) and eIF4G and to show that overexpression of eIF4E in cultural mammalian cells leads to rapid, dysregulated cell growth. Dr. Rhoads has served as chair of NIH study sections, chair of the Publications Committee of the American Society for Biochemistry and Molecular Biology, and President of the Association of Medical and Graduate Departments of Biochemistry. He is co-inventor on four issued patents and two pending patents that deal with protein purification, protein expression, and mRNA stabilization. He earned his B.A. in chemistry at Rice University and Ph.D. in biochemistry at George Washington University and then was an American Cancer Society postdoctoral fellow at Stanford University.